Lucy Therapeutics
Lucy Therapeutics is a mitochondrial platform company focused on small molecule treatments for Rett Syndrome and Parkinson’s Disease, leveraging a unique peripheral mitochondrial biomarker. LucyTx’s platform has led to the discovery of targets which can improve central energetic dysfunctions in these diseases and address their complex organ symptomatology. LucyTx interrogates complex biology with well-defined molecules to answer key questions about the pathways critical for disease modification.